Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.76 |
| ▸ | PTPRS | Q13332 | 5/20 | 0.76 |
| ▸ | AMY1A | P0DUB6 | 4/20 | 0.76 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.76 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.76 |
| ▸ | FTO | Q9C0B1 | 3/20 | 0.76 |
| ▸ | GABRP | O00591 | 2/20 | 0.76 |
| ▸ | GABRD | O14764 | 2/20 | 0.76 |
| ▸ | FBP1 | P09467 | 2/20 | 0.76 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.76 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.76 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.76 |
| ▸ | UGT1A1 | P22309 | 2/20 | 0.76 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.76 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.76 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.76 |
| ▸ | GRK6 | P43250 | 2/20 | 0.76 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.76 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.76 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 6-Hydroxyluteolin SCHEMBL30217544 | 1.00 | KMT2A (0.76) | KMT2APTPRSAMY1ACYP1A1CYP1B1 | |
| 6-Hydroxyluteolin SCHEMBL29887622 | 1.00 | KMT2A (0.76) | KMT2APTPRSAMY1ACYP1A1CYP1B1 | |
| 6-Hydroxyluteolin SCHEMBL29929561 | 1.00 | KMT2A (0.76) | KMT2APTPRSAMY1ACYP1A1CYP1B1 | |
| SCHEMBL11662442 | 0.87 | PTPRS (0.74) | KMT2APTPRSAMY1ACYP1A1CYP1B1 | |
| SCHEMBL5981301 | 0.87 | ABCB1 (0.73) | KMT2APTPRSAMY1ACYP1A1CYP1B1 | |
| Scutellarein SCHEMBL29004586 | 0.86 | KMT2A (1.00) | KMT2APTPRSAMY1ACYP1A1CYP1B1 | |
| Scutellarein SCHEMBL142093 | 0.86 | KMT2A (1.00) | KMT2APTPRSAMY1ACYP1A1CYP1B1 | |
| Scutellarein SCHEMBL29692708 | 0.86 | KMT2A (1.00) | KMT2APTPRSAMY1ACYP1A1CYP1B1 | |
| Scutellarein SCHEMBL1900314 | 0.85 | KMT2A (0.97) | KMT2APTPRSAMY1ACYP1A1CYP1B1 | |
| Scutellarein SCHEMBL15090395 | 0.85 | KMT2A (0.97) | KMT2APTPRSAMY1ACYP1A1CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4698662-A2 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | AskBio Inc. (US) | 2026-02-25 | — | — | EP | claimed |
| WO-2024220449-A9 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | AskBio Inc. (US) | 2025-04-03 | — | — | WO | claimed |
| US-20250011393-A1 | FLAVONOID-COLLAGEN CROSSLINKED ANTIOXIDANT HYDROGEL | NORTH CAROLINA STATE UNIVERSITY | 2025-01-09 | — | — | US | claimed |
| US-12163004-B2 | Polymer composites | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2024-12-10 | — | — | US | claimed |
| WO-2024220449-A2 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | ASKLEPIOS BIOPHARMACEUTICAL, INC. (US) | 2024-10-24 | — | — | WO | claimed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| WO-2023219526-A1 | MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT | PROKIN MILAN (RS) | 2023-11-16 | — | — | WO | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| WO-2022182523-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| US-20030118536-A1 | Topical compositions and methods for treatment of adverse effects of ionizing radiation | QUIGLEY CORPORATION, THE | 2003-06-26 | — | — | US | claimed |
| US-20030105031-A1 | Methods for the treatment of skin disorders | QUIGLEY CORPORATION, THE | 2003-06-05 | — | — | US | claimed |
| US-20030103954-A1 | Oral compositions and methods for prevention, reduction and treatment of radiation injury | QUIGLEY CORPORATION, THE | 2003-06-05 | — | — | US | claimed |
| US-20030105027-A1 | Nutritional supplements and methods for prevention, reduction and treatment of radiation injury | QUIGLEY CORPORATION, THE | 2003-06-05 | — | — | US | claimed |
| WO-2003039452-A2 | NUTRITIONAL SUPPLEMENTS AND METHODS FOR PREVENTION, REDUCTION AND TREATMENT OF RADIATION INJURY | THE QUIGLEY CORPORATION (US) | 2003-05-15 | — | — | WO | claimed |
| US-6555573-B2 | Comprising a cold compounded mixture of a compound that promotes synthesis of nerve growth factor, an aldose reductase inhibitor, antioxidant and carrier; side effect reduction; partial recovery of neurological function in some cases | THE QUIGLEY CORPORATION | 2003-04-29 | — | — | US | claimed |
| US-20020165207-A1 | Compositions and methods for the treatment of diabetic neuropathy | QUIGLEY CORPORATION, THE | 2002-11-07 | — | — | US | claimed |
| US-6451837-B1 | Neuroprotective effects of mitogen-activated protein kinase (MAPK) cascade inhibitors | BASKYS ANDRIUS (US) | 2002-09-17 | — | — | US | claimed |
| US-20020115618-A1 | Method and composition for the topical treatment of diabetic neuropathy | QUIGLEY CORPORATION, THE | 2002-08-22 | — | — | US | claimed |
| WO-2002049575-A2 | METHOD AND COMPOSITION FOR THE TREATMENT OF DIABETIC NEUROPATHY | THE QUIGLEY CORPORATION (US) | 2002-06-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030103954-A1 | Oral compositions and methods for prevention, reduction and treatment of radiation injury | FOXO3, BAX, GSTK1 | KMT2A 4811/4885PTPRS 4470/4885AMY1A 2042/4885 |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | KMT2A 4742/4885PTPRS 4527/4885AMY1A 1499/4885 |
| US-20030105027-A1 | Nutritional supplements and methods for prevention, reduction and treatment of radiation injury | FOXO3, NQO1, FOXO1 | KMT2A 4745/4885PTPRS 4377/4885AMY1A 2369/4885 |
| US-20030105031-A1 | Methods for the treatment of skin disorders | TYR, CUTA, NFATC1 | KMT2A 2226/4885PTPRS 1394/4885AMY1A 3483/4885 |
| US-20030118536-A1 | Topical compositions and methods for treatment of adverse effects of ionizing radiation | GSTK1, FOXO3, SIK2 | KMT2A 4723/4885PTPRS 4425/4885AMY1A 2692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.